@HypoResolve on May 19, 2022
Hypo-RESOLVE granted 18 months’ project extension
The Hypo-RESOVLE consortium is very pleased to announce that the IMI approved an 18 months’ no-cost extension of the Hypo-RESOLVE action end of April 2022. The project will now terminate in October 20...
Hypo-RESOLVE Virtual Managing Board Meeting
On 15th March 2022, the Hypo-RESOLVE Managing Board gathered online to discuss the action’s progress and plan work for the no-cost project extension, which has been requested with the IMI2 JU to allow...
Podcast Series: Episode 8 on fostering dialogue between regulators like the European Medicines Agency (EMA) and the Hypo-RESOLVE project
Making sure that the Hypo-RESOLVE results change the diabetes (research) landscape for the better, is one of our most important goals. For our last episode, we have invited Jens Heisterberg from Novo...
Podcast Series: Episode 7 on the Development of Patient-Reported Outcome Measures (PROs) in Hypoglycaemia
Patient-Reported Outcome (PRO) Measures reliably assess the psychological impact of hypoglycaemia. Our seventh episode features researchers Dr Jill Carlton and Dr Philip Powell from the University of...
Podcast Series: Episode 6 on the Psychological Burden of Hypoglycaemia
Diabetes and hypoglycaemia extend beyond physical effects and can become a psychological burden as well. Today’s episode features Melanie Broadley from the University of Southern Denmark and Renza Sci...
Podcast Series: Episode 5 on the Hypo-METRICS Study
What are the implications of hypoglycaemic episodes that are underneath the detection threshold of current glucose measuring devices? This is what the Hypo-METRICS study set out to determine. Our podc...